NASDAQ:ZGNX - Zogenix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$40.75 -0.50 (-1.21 %)
(As of 05/22/2018 03:40 AM ET)
Previous Close$40.75
Today's Range$40.15 - $42.00
52-Week Range$10.05 - $45.85
Volume478,193 shs
Average Volume555,954 shs
Market Capitalization$1.45 billion
P/E Ratio-10.14
Dividend YieldN/A
Beta1.7

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Debt-to-Equity RatioN/A
Current Ratio12.19
Quick Ratio12.19

Price-To-Earnings

Trailing P/E Ratio-10.14
Forward P/E Ratio-10.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales146.15
Cash FlowN/A
Price / CashN/A
Book Value$8.80 per share
Price / Book4.63

Profitability

EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-66.94%
Return on Assets-40.43%

Miscellaneous

Employees68
Outstanding Shares35,220,000

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix (NASDAQ:ZGNX) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.13. During the same quarter in the prior year, the business posted ($0.86) EPS. View Zogenix's Earnings History.

What price target have analysts set for ZGNX?

5 brokers have issued 1-year price objectives for Zogenix's shares. Their predictions range from $51.00 to $56.00. On average, they expect Zogenix's share price to reach $54.00 in the next year. View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. Mizuho analysts commented, "We are confident ahead of this data and we expect the readout to be an important share moving event and the last major hurdle prior to submission of the NDA." (5/10/2018)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (3/15/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Mr. Cam L. Garner, Co-founder & Chairman (Age 70)
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)

Has Zogenix been receiving favorable news coverage?

News coverage about ZGNX stock has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zogenix earned a news sentiment score of 0.05 on Accern's scale. They also assigned media headlines about the company an impact score of 46.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (9.86%), BlackRock Inc. (7.48%), Farallon Capital Management LLC (4.47%), venBio Select Advisor LLC (3.38%), Eagle Asset Management Inc. (2.84%) and Franklin Resources Inc. (2.50%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, venBio Select Advisor LLC, BlackRock Inc., DAFNA Capital Management LLC, JPMorgan Chase & Co., Highland Capital Management LP, Eversept Partners LLC and Gagnon Securities LLC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner and Roger Hawley. View Insider Buying and Selling for Zogenix.

Which major investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Artal Group S.A., GW&K Investment Management LLC, Point72 Asset Management L.P., Eventide Asset Management LLC, Millennium Management LLC, Scopia Capital Management LP and Cheyne Capital Management UK LLP. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $40.75.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.45 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (ZGNX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zogenix (NASDAQ:ZGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Zogenix in the last 12 months. Their average twelve-month price target is $54.00, suggesting that the stock has a possible upside of 32.52%. The high price target for ZGNX is $56.00 and the low price target for ZGNX is $51.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $54.00$54.00$48.00$46.00
Price Target Upside: 32.52% upside22.73% upside32.05% upside21.69% upside

Zogenix (NASDAQ:ZGNX) Consensus Price Target History

Price Target History for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018MizuhoReiterated RatingBuy$51.00HighView Rating Details
3/4/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
11/27/2017JMP SecuritiesInitiated CoverageOutperform$56.00MediumView Rating Details
9/29/2017Stifel NicolausReiterated RatingBuy$26.00 ➝ $55.00N/AView Rating Details
9/29/2017William BlairUpgradeMarket Perform ➝ OutperformN/AView Rating Details
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Zogenix (NASDAQ:ZGNX) Earnings History and Estimates Chart

Earnings by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.00)
2019 EPS Consensus Estimate: ($3.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.78)($0.66)($0.72)
Q2 20182($0.93)($0.90)($0.92)
Q3 20182($1.00)($0.92)($0.96)
Q4 20182($1.81)($0.99)($1.40)
Q1 20191($1.10)($1.10)($1.10)
Q2 20191($1.11)($1.11)($1.11)
Q3 20191($0.85)($0.85)($0.85)
Q4 20191($0.63)($0.63)($0.63)

Zogenix (NASDAQ ZGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.74)($0.87)ViewN/AView Earnings Details
3/6/2018Q4 2017($0.97)($1.14)ViewListenView Earnings Details
11/7/2017Q3 2017($0.95)($1.11)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.90)$3.48 million$7.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.84)($0.73)$5.05 million$10.99 millionViewN/AView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
8/10/2011Q2 2011($4.16)($4.51)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zogenix (NASDAQ:ZGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zogenix (NASDAQ ZGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 99.36%
Insider Trading History for Zogenix (NASDAQ:ZGNX)
Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ ZGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Cam L GarnerDirectorSell218$39.90$8,698.20View SEC Filing  
3/13/2018Roger HawleyDirectorSell35,000$44.71$1,564,850.00View SEC Filing  
12/13/2017Bradley S. GalerEVPBuy1,346$36.59$49,250.14View SEC Filing  
12/11/2017Roger HawleyDirectorSell63,203$36.84$2,328,398.52105,575View SEC Filing  
12/8/2017Roger HawleyDirectorSell11,797$37.02$436,724.94105,575View SEC Filing  
10/3/2017Life Sciences Maste PerceptiveMajor ShareholderBuy300,000$37.50$11,250,000.00View SEC Filing  
9/29/2017Life Sciences Maste PerceptiveMajor ShareholderBuy222,055$32.83$7,290,065.65View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy175,653$14.45$2,538,185.85View SEC Filing  
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.0010,000View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.001,404,447View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.0079,500View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zogenix (NASDAQ ZGNX) News Headlines

Source:
DateHeadline
Zogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by AnalystsZogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 15 at 5:34 AM
Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare ConferenceZogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
globenewswire.com - May 14 at 9:10 AM
Leerink Swann Equities Analysts Lower Earnings Estimates for Zogenix, Inc. (ZGNX)Leerink Swann Equities Analysts Lower Earnings Estimates for Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - May 14 at 1:17 AM
Q2 2018 EPS Estimates for Zogenix, Inc. Lowered by Analyst (ZGNX)Q2 2018 EPS Estimates for Zogenix, Inc. Lowered by Analyst (ZGNX)
www.americanbankingnews.com - May 14 at 1:17 AM
Research Analysts Offer Predictions for Zogenix, Inc.s FY2021 Earnings (ZGNX)Research Analysts Offer Predictions for Zogenix, Inc.'s FY2021 Earnings (ZGNX)
www.americanbankingnews.com - May 11 at 11:47 AM
Zogenix (ZGNX) Releases  Earnings Results, Misses Estimates By $0.13 EPSZogenix (ZGNX) Releases Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - May 10 at 6:33 PM
Zogenixs (ZGNX) "Buy" Rating Reiterated at MizuhoZogenix's (ZGNX) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - May 10 at 11:28 AM
Zogenixs (ZGNX) CEO Stephen Farr on Q1 2018 Results - Earnings Call TranscriptZogenix's (ZGNX) CEO Stephen Farr on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:56 AM
Edited Transcript of ZGNX earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of ZGNX earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:56 AM
BRIEF-Zogenix Q1 Loss Per Share $0.87BRIEF-Zogenix Q1 Loss Per Share $0.87
www.reuters.com - May 9 at 5:06 PM
Zogenix Provides Corporate Update and Reports First Quarter Financial ResultsZogenix Provides Corporate Update and Reports First Quarter Financial Results
finance.yahoo.com - May 9 at 5:06 PM
Zogenix: 1Q Earnings SnapshotZogenix: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:06 PM
Financial Contrast: Zogenix (ZGNX) versus Recro Pharma (REPH)Financial Contrast: Zogenix (ZGNX) versus Recro Pharma (REPH)
www.americanbankingnews.com - May 9 at 3:49 PM
-$0.74 Earnings Per Share Expected for Zogenix, Inc. (ZGNX) This Quarter-$0.74 Earnings Per Share Expected for Zogenix, Inc. (ZGNX) This Quarter
www.americanbankingnews.com - May 7 at 8:06 AM
Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
finance.yahoo.com - May 4 at 8:46 AM
Zogenix (ZGNX) Upgraded to "Strong-Buy" at ValuEngineZogenix (ZGNX) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 1:15 PM
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - May 2 at 8:49 AM
Zogenix (ZGNX) Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ...Zogenix (ZGNX) Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ...
www.streetinsider.com - April 26 at 8:41 AM
Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies ...Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies ...
globenewswire.com - April 25 at 8:46 AM
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 ...Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 ...
globenewswire.com - April 25 at 8:46 AM
BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ...BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ...
www.reuters.com - April 25 at 8:46 AM
Zogenix (ZGNX) Upgraded by BidaskClub to "Buy"Zogenix (ZGNX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 20 at 11:17 AM
Stock Traders Purchase High Volume of Zogenix Put Options (ZGNX)Stock Traders Purchase High Volume of Zogenix Put Options (ZGNX)
www.americanbankingnews.com - April 20 at 7:13 AM
Zogenix Target of Unusually Large Options Trading (ZGNX)Zogenix Target of Unusually Large Options Trading (ZGNX)
www.americanbankingnews.com - April 20 at 7:08 AM
Zogenix, Inc. (ZGNX) Given Average Rating of "Buy" by BrokeragesZogenix, Inc. (ZGNX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 20 at 5:35 AM
Zogenix, Inc. (ZGNX) Expected to Post Earnings of -$0.74 Per ShareZogenix, Inc. (ZGNX) Expected to Post Earnings of -$0.74 Per Share
www.americanbankingnews.com - April 20 at 5:21 AM
KOL Epilepsy Lunch Confirms Zogenix (ZGNX) Fenfluramine Efficacy - StifelKOL Epilepsy Lunch Confirms Zogenix (ZGNX) Fenfluramine Efficacy - Stifel
www.streetinsider.com - April 19 at 8:46 AM
Brokers Issue Forecasts for Zogenix, Inc.s FY2019 Earnings (ZGNX)Brokers Issue Forecasts for Zogenix, Inc.'s FY2019 Earnings (ZGNX)
www.americanbankingnews.com - April 18 at 8:52 AM
Zogenix (ZGNX) Rating Lowered to Buy at BidaskClubZogenix (ZGNX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 17 at 12:21 PM
Zogenix to Participate in LEERINK Partners CNS DayZogenix to Participate in LEERINK Partners CNS Day
finance.yahoo.com - April 11 at 9:13 AM
Zogenix (ZGNX) Lowered to "Hold" at BidaskClubZogenix (ZGNX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM
Zogenix (ZGNX) Upgraded to "Hold" by ValuEngineZogenix (ZGNX) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 10 at 8:47 AM
Forty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial OfficerForty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial Officer
www.prnewswire.com - April 3 at 8:57 AM
Zogenix (ZGNX) Upgraded at ValuEngineZogenix (ZGNX) Upgraded at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Wired News – Shire Collaborates with NanoMedSyn to Treat Potential Lysosomal Storage DisorderWired News – Shire Collaborates with NanoMedSyn to Treat Potential Lysosomal Storage Disorder
finance.yahoo.com - March 28 at 9:02 AM
Zogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by AnalystsZogenix, Inc. (ZGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 26 at 5:40 AM
Zogenix (ZGNX) Given Buy Rating at MizuhoZogenix (ZGNX) Given Buy Rating at Mizuho
www.americanbankingnews.com - March 25 at 10:22 PM
Zogenix (ZGNX) Rating Increased to Buy at Zacks Investment ResearchZogenix (ZGNX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:50 PM
Zogenix, Inc. (ZGNX) Director Sells $1,564,850.00 in StockZogenix, Inc. (ZGNX) Director Sells $1,564,850.00 in Stock
www.americanbankingnews.com - March 14 at 7:12 PM
Zogenixs (ZGNX) Buy Rating Reaffirmed at MizuhoZogenix's (ZGNX) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 11 at 1:16 PM
Employee Stock Options Liability Significant For ZogenixEmployee Stock Options Liability Significant For Zogenix
finance.yahoo.com - March 9 at 6:13 PM
Q1 2018 EPS Estimates for Zogenix, Inc. (ZGNX) Raised by AnalystQ1 2018 EPS Estimates for Zogenix, Inc. (ZGNX) Raised by Analyst
www.americanbankingnews.com - March 9 at 8:52 AM
Zogenix, Inc. (ZGNX) Expected to Earn Q1 2018 Earnings of ($0.78) Per ShareZogenix, Inc. (ZGNX) Expected to Earn Q1 2018 Earnings of ($0.78) Per Share
www.americanbankingnews.com - March 9 at 8:52 AM
Zogenix, Inc. (ZGNX) Forecasted to Earn Q1 2019 Earnings of ($0.91) Per ShareZogenix, Inc. (ZGNX) Forecasted to Earn Q1 2019 Earnings of ($0.91) Per Share
www.americanbankingnews.com - March 8 at 11:28 AM
Why Zogenix Inc. Shares Shot Up 16.6% in February - Motley FoolWhy Zogenix Inc. Shares Shot Up 16.6% in February - Motley Fool
www.fool.com - March 7 at 5:56 PM
Zogenix (ZGNX) Releases  Earnings Results, Misses Expectations By $0.17 EPSZogenix (ZGNX) Releases Earnings Results, Misses Expectations By $0.17 EPS
www.americanbankingnews.com - March 7 at 1:25 PM
Zogenix (ZGNX) Stock Rating Reaffirmed by Leerink SwannZogenix (ZGNX) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - March 7 at 11:33 AM
Zogenix, Inc. Forecasted to Post FY2017 Earnings of ($4.17) Per Share (ZGNX)Zogenix, Inc. Forecasted to Post FY2017 Earnings of ($4.17) Per Share (ZGNX)
www.americanbankingnews.com - March 7 at 7:26 AM
Why Zogenix Inc. Shares Shot Up 16.6% in FebruaryWhy Zogenix Inc. Shares Shot Up 16.6% in February
finance.yahoo.com - March 6 at 5:18 PM
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial ResultsZogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 6 at 5:18 PM

SEC Filings

Zogenix (NASDAQ:ZGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zogenix (NASDAQ:ZGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zogenix (NASDAQ ZGNX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.